🇺🇸

US SEC Filing Intelligence

· monthly

US Pre-Market SEC Filings Roundup — May 28, 2026

The overnight filing period from May 27-28, 2026, reveals a market bifurcated between aggressive capital deployment and financial distress. A dominant theme is the surge in SPAC and de-SPAC activity, with three major business combinations announced or completed: Pasqal (quantum computing) targeting a $2B valuation, NewCleo (nuclear technology) merging with NewHold, and Hadron Energy (micro-reactors) completing its merger with GigCapital7. This is complemented by IBM's $10B quantum computing investment, signaling a strong institutional push into next-gen energy and compute. On the earnings front, consumer-facing companies like Dollar Tree (+7.2% revenue) and Burlington (+14% revenue) show robust top-line growth, but margin pressures are evident across the board, with HP Inc. seeing a 6.4% decline in operating earnings despite 9% revenue growth. The most critical risk signals emanate from deep financial distress at ZRCN Inc. (net loss widening to $1.9B) and Nature's Miracle Holding (debt settlement with 27% reduction but severe cash constraints). Insider activity is notably absent from filings, but capital allocation patterns are stark: Salesforce repurchased $27.4B in stock, while Hyperscale Data raised funds at a dilutive $0.18/share. The overarching theme is a 'haves vs. have-nots' market where strong balance sheets are being used aggressively for M&A and buybacks, while cash-strapped companies resort to dilutive financing and distressed settlements.

30 high priority 20 medium 50 total filings
· daily

NME Blockbuster Approvals — May 27, 2026

This period covers a single FDA approval: Gilead Sciences' BULEVIRTIDE-GMOD (HEPCLUDEX), an NME with Priority Review and Orphan Drug designations for an undisclosed indication. While the approval mix shows no biosimilar or label expansion activity, this NME represents a bullish signal for Gilead, leveraging its established virology franchise. The highest-conviction signal is the approval itself, which strengthens Gilead's pipeline credibility in a high-unmet-need area, though the lack of disclosed peak sales estimates and pricing power limits near-term commercial conviction. Key watch items include payer coverage decisions and the drug's market positioning against existing hepatitis therapies.

1 total filings
· daily

Big Pharma Approvals — May 27, 2026

This period covers a single FDA approval on May 22, 2026: Gilead Sciences Inc’s BULEVIRTIDE-GMOD (HEPCLUDEX), classified as an NME with Priority Review and Orphan Drug designations. The approval is a bullish signal for Gilead, reinforcing its therapeutic area strength in virology and hepatitis B virus (HBV) treatment. No biosimilars or label expansions were approved, making this a narrowly focused event. The key risk is the lack of disclosed peak sales estimates, pricing power, and market position data, which limits full commercial assessment. Investors should watch for Gilead’s launch execution and payer coverage decisions to gauge revenue potential.

1 total filings
· daily

Orphan Drug Approvals — May 27, 2026

The May 27, 2026 orphan drug approval period featured a single approval: Gilead Sciences Inc’s BULEVIRTIDE-GMOD (HEPCLUDEX), an NME granted Priority Review and Orphan Drug designation for an undisclosed indication. While the approval mix shows zero biosimilars or label expansions, the lone NME represents a high-conviction signal given Gilead’s established virology franchise and the regulatory priority assigned. The key bullish signal is the NME’s potential to address an unmet need in a niche orphan population, though the lack of disclosed peak sales estimates, pricing power, and market position data tempers conviction. The key risk is the absence of commercial detail, leaving uncertainty around revenue contribution and competitive dynamics within Gilead’s portfolio.

1 total filings
· daily

New Drug Approvals (Original) — May 27, 2026

During the single-day period of May 27, 2026, the FDA approved one new drug application classified as 'Other' (FALLBACK type), with zero NMEs, biosimilars, or label expansions. The sole approval was Gilead Sciences' BULEVIRTIDE-GMOD (HEPCLUDEX), a Priority Review and Orphan Drug-designated therapy for an undisclosed hepatitis indication. This approval signals a bullish, albeit niche, commercial opportunity for Gilead in a high-unmet-need area, but the lack of disclosed peak sales estimates, pricing power, or market position data limits conviction. The key watch item is Gilead's ability to commercialize this orphan drug in a competitive hepatitis landscape, where pricing and patient access remain critical unknowns.

1 total filings
· daily

New Federal Contractors — May 27, 2026

The single contract in this period, a $104.3M cost-plus-fixed-fee delivery order awarded to Quantech Services Inc. by the GSA, is defense-related and supports the Space and Missile Systems Center (SMC), signaling stable demand for space systems R&D support. The contract is neutral in signal strength (5/10) due to its cost-plus structure, which limits profit upside but reduces execution risk, and a concerning negative outlayed amount (-$5,427) that may indicate funding delays or accounting issues. The small business designation suggests niche positioning, but the full-and-open competition (after exclusion of sources) implies competitive pressure. Key risks include monitoring future outlays to confirm funding flow and the contract's performance through August 2024. No bullish or bearish signals were identified, making this a watch-and-verify situation for investors tracking defense space services exposure.

1 total filings
· daily

Significant Contract Modifications ($10M+) — May 27, 2026

This digest covers a single $104.3M cost-plus-fixed-fee delivery order awarded to Quantech Services Inc. by the General Services Administration (GSA) for Space and Missile Systems Center (SMC) acquisition and financial support. The contract is 100% defense-related, reflecting stable spending in space systems R&D, but the cost-plus structure limits margin upside. The most notable signal is the near-zero outlayed amount (-$5,427), suggesting the contract is in an early stage or faces funding delays, which warrants caution. No bullish or bearish signals are present; the neutral signal strength (5/10) and low materiality (4/10) indicate limited near-term investment impact. Key risk is execution uncertainty tied to funding flow, while the opportunity lies in Quantech's niche positioning in priority defense space programs.

1 total filings
· daily

Contract Deobligations Alert — May 27, 2026

The single contract digest for May 27, 2026, reports a $104.3M deobligation from the General Services Administration (GSA) to Quantech Services Inc., a small business, for Space and Missile Systems Center (SMC) acquisition support. This is a defense-related award with a cost-plus-fixed-fee pricing structure, which limits profit upside but reduces execution risk. The neutral signal (strength 5/10, materiality 4/10) reflects the contract's early-stage funding anomaly—only -$5,427 outlayed—raising questions about cash flow timing or accounting adjustments. The key risk is monitoring future outlays to confirm the contract is fully funded and performing as expected, particularly given the 2024 performance end date and potential CR exposure for space systems spending.

1 total filings
· daily

Contract Option Exercises — May 27, 2026

This digest covers a single $104.3 million contract option exercise period on May 27, 2026, with 100% defense-related spending. The dominant signal is a neutral, cost-plus-fixed-fee delivery order awarded to Quantech Services Inc. by the GSA for Space and Missile Systems Center (SMC) acquisition support. The highest-conviction signal is the contract's tie to stable space systems R&D, a priority defense area, but the near-zero outlayed amount (-$5,427) raises caution about funding flow or accounting anomalies. Key risk is the early-stage funding status, which could indicate execution delays or budget constraints despite the large obligation ceiling.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — May 27, 2026

This digest covers a single $104.3M mega contract awarded to Quantech Services Inc. by the General Services Administration (GSA) for acquisition and financial support to the Space and Missile Systems Center (SMC). The contract is entirely defense-related, reflecting stable demand for space systems R&D support. The highest-conviction signal is neutral given the cost-plus-fixed-fee pricing structure that limits profit upside but reduces risk. A key risk is the near-zero outlayed amount (-$5,427), suggesting minimal initial funding or a potential accounting anomaly that warrants monitoring for cash flow execution.

1 total filings
· daily

High-Value Federal Grants ($5M+) — May 27, 2026

The digest covers a single, defense-related contract from the General Services Administration (GSA) valued at $104.3M, awarded to Quantech Services Inc. for support of the Space and Missile Systems Center (SMC). The cost-plus-fixed-fee pricing structure reduces profit risk but caps margin upside, while the negative outlayed amount (-$5,427) signals either an early-stage funding anomaly or a potential execution risk. This contract aligns with stable DOD space systems spending, but the lack of follow-on outlays and the small business designation warrant cautious monitoring. The overall signal is neutral, with no bullish or bearish catalysts identified from this single award.

1 total filings
· daily

General Federal Contracts — May 27, 2026

This digest covers a single $104.3M cost-plus-fixed-fee delivery order awarded to Quantech Services Inc. by the General Services Administration (GSA) for Space and Missile Systems Center (SMC) acquisition support. The contract is entirely defense-related, reflecting stable demand for space systems R&D support, a priority area under the NDAA. However, the contract's neutral signal strength (5/10) and minimal initial outlay (-$5,427) raise execution and funding flow concerns. The cost-plus structure limits profit upside but reduces risk, while Quantech's small business status suggests niche positioning in a competitive market. Key watch items include monitoring future outlay amounts and option exercises before August 2024.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 27, 2026

The 32 filings for the S&P 500 Technology stream reveal a sector bifurcated between AI-driven growth leaders and companies facing margin pressure from acquisition integration and restructuring. Salesforce and Snowflake posted strong revenue beats (13% and 33% YoY, respectively), but both guided for deceleration, signaling a potential top in growth rates. Synopsys reported a 42% revenue surge from the Ansys acquisition, but GAAP net income collapsed 95% due to massive amortization and restructuring charges, highlighting the cost of M&A-driven growth. Insider activity is sparse, but the appointment of an activist investor (Elliott) to Synopsys' board signals a push for operational efficiency. A significant risk flag is the unsolicited tender offer for Genco Shipping, where less than 1% of shares have been tendered despite a raised offer, indicating shareholder skepticism. The most actionable opportunity is Salesforce's massive $25B ASR, which, combined with its record margins, suggests management sees the stock as undervalued. Sector-wide, capital allocation is shifting from reinvestment to shareholder returns, with buybacks and dividends dominating, while M&A integration costs are creating earnings headwinds.

8 high priority 24 medium 32 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 27, 2026

The May 27, 2026, filing batch for the NASDAQ-100 stream is dominated by routine corporate actions (AGM results, debt offerings, and delayed 13F filings), but two high-conviction themes emerge: a hostile takeover battle in the dry bulk shipping sector and a strategic CEO appointment at a late-stage biotech. Genco Shipping & Trading is the focal point, with Diana Shipping raising its hostile bid to $24.80/share (a 39% premium) while facing near-zero shareholder tenders (0.0002% of shares), setting up a critical proxy fight at the June 18 AGM. In biotech, Immunic's appointment of a Genentech/Roche veteran as CEO, with a pivotal Phase 3 data readout and potential NDA filing by year-end, presents a high-risk/high-reward catalyst. The remaining filings are largely low-materiality, with eight delayed 13F filings from Kentucky Farm Bureau (2016-2018) offering no current trading insights, and several AGM results showing minor shareholder dissent (6-23% withhold votes) but no material impact. Capital allocation signals are mixed: Apple Hospitality REIT extended a $242.5M buyback, while Murphy USA issued $500M in new 5.875% debt, indicating a refinancing or growth capex need.

4 high priority 25 medium 29 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 27, 2026

The 50 filings from S&P 500 Financials and adjacent sectors reveal a broad divergence between companies with robust growth and those in distress. Notably, Dycom Industries and Marvell Technology reported exceptional revenue growth (+56% and +28% YoY, respectively) driven by acquisitions and AI demand, while Trillion Energy and Hi-Great Group posted massive losses. Capital allocation trends show a split: Movado raised dividends 14%, while Dick's Sporting Goods cut buybacks 53% amid acquisition integration. Insider activity was limited, but Nukkleus faces Nasdaq delisting, and several biotechs (Apogee, Immunic) advanced pivotal catalysts. M&A activity is picking up, with Worthington Steel cleared to close its German acquisition and GameStop's bold $125/share bid for eBay. Portfolio-level patterns indicate that operational efficiency is under pressure, with Home Depot and Abercrombie & Fitch seeing margin compression despite revenue gains. Overall, the data suggests investors should favor names with clear growth catalysts and vigilant cash management, while avoiding firms with going-concern risks or unprofitable core operations.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 27, 2026

The 50 filings for the S&P 500 Consumer Staples stream reveal a sector bifurcated between defensive stability and operational restructuring. While core consumer names like **Movado Group** show robust top-line growth (8.1% YoY) and margin expansion (+320 bps), others like **Monro, Inc.** are navigating significant store closures and sales declines (-7.2% YoY) to improve profitability. A key theme is capital discipline, with **Movado** raising its dividend by 14% and **Molson Coors** executing a $2.5B debt refinancing, contrasting with **Nature's Miracle**'s near-total revenue collapse (96% YoY). Notable activist resolution at **lululemon** with founder Chip Wilson adds a governance catalyst. The most material event is the $3.8B SPAC merger for solid-state battery developer **ProLogium**, signaling a major bet on next-gen energy storage. Overall, the sector presents a 'show-me' story where cost-cutting and balance sheet management are driving near-term results, while top-line growth remains uneven and heavily dependent on specific product cycles and foreign exchange.

19 high priority 31 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 27, 2026

The 50 filings from the S&P 500 Industrials stream reveal a market bifurcated between growth-oriented companies (energy transition, infrastructure, and biotech) and consumer-facing firms experiencing demand softness. Revenue growth is present across 6 of 10 reporting companies, with AMSC (+34% YoY) and Transcat (+19% YoY) leading, but margin compression is a pervasive theme—Home Depot (-120 bps OM), Bath & Body Works (-280 bps GM), Transcat (-240 bps OM), and G-III Apparel (not reported) all show cost pressures eating into profitability. Capital markets remain active: two major SPAC mergers (ProLogium at $3.8B, Stellar/Prosperity) and a $3.5B take-private (Veris Residential) highlight deal flow, while Apogee secured $1.3B in non-dilutive financing. Insider signals are sparse but notable—Jessica Alba at Honest Company received 55% withheld votes, a potential governance red flag. The overarching theme is that industrial companies tied to grid modernization (AMSC, Oncor) and defense/energy infrastructure are outperforming traditional retail and office REITs, with forward guidance generally cautious (Bath & Body Works maintains negative sales outlook, Phreesia kept revenue range flat despite 13% growth).

28 high priority 22 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 27, 2026

The five filings for the S&P 500 Energy stream on May 27, 2026, present a mixed but actionable picture. The most material development is Cheniere Energy's $1.75 billion debt refinancing, where the subsidiary is issuing new notes at higher coupons (5.350% and 6.050%) to redeem $1.5 billion in 5.00% notes due 2027, reflecting a significant increase in long-term borrowing costs (+35 to +105 bps). This is a clear signal of rising interest rate pressure on energy infrastructure debt. Meanwhile, Cheniere Energy Partners (CQP) announced a separate, unregistered offering, creating potential confusion about the total debt stack. The Copper Property Trust filing is purely procedural, offering no new financial data. IIOT-OXYS, a micro-cap, continues to show financial distress with its seventh extension of a $75,000 convertible note, pushing maturity to October 2026. The Capasso Planning Partners 13F reveals a conservative, fixed-income-heavy portfolio with minimal direct energy exposure, suggesting institutional caution. The dominant theme is capital structure management in a high-rate environment, with no period-over-period growth data or insider activity to offset the refinancing cost pressures.

3 high priority 2 medium 5 total filings
· daily

US Material Events SEC 8-K Filings — May 27, 2026

The 50 filings reveal a market bifurcated between capital-intensive growth plays and defensive restructuring. Key themes include a surge in non-dilutive and alternative financing (Apogee, Bit Digital, WhiteFiber), SPAC activity (Translational Development/Oceanhawk), and significant insider/board changes signaling strategic pivots (lululemon, Synopsys, Immunic). Period-over-period data shows mixed consumer health: Bath & Body Works reported a 3% YoY revenue decline and 280 bps gross margin compression, while Agilent posted 10% revenue growth and 130 bps margin expansion. Capital allocation trends are defensive, with debt refinancings (Molson Coors, Oncor) and ATM offerings (Data Storage, Callan JMB, Minerva) common. Notable M&A includes Veris Residential's $3.5B take-private and BuzzFeed's $120M majority stake sale. Forward-looking statements highlight key catalysts: Immunic's Phase 3 RMS data (YE2026), ProLogium's SPAC merger (H2 2026), and Apogee's milestone-driven $1.3B financing. Insider activity is limited, but board appointments at Synopsys (Elliott partner) and lululemon (activist settlement) signal governance shifts. Overall, the digest points to a market favoring companies with clear catalysts and strong balance sheets, while consumer-facing and early-stage biotech face headwinds.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 27, 2026

The 50 filings for the Dow 30 stream reveal a bifurcated earnings landscape: while technology leaders like Salesforce and Marvell deliver record revenue and surging AI-driven growth, consumer-facing names like Bath & Body Works and U-Haul show clear signs of demand softening and margin compression. A dominant theme is the aggressive pivot toward AI and data infrastructure, with Salesforce's Agentforce ARR surging over 200% YoY and Marvell raising its outlook on AI demand, even as capital allocation shifts heavily toward buybacks and debt financing. Several filings highlight significant insider activity and governance changes, including a notable retraction of a credit facility announcement from Fold Holdings and a major $3.5B take-private acquisition of Veris Residential. Period-over-period comparisons reveal a mixed picture: revenue growth is present but often comes at the cost of compressed margins (e.g., Home Depot's sales up 4.8% but operating income down 3.0%), while capital markets activity remains robust with large debt issuances from Oncor and Molson Coors. The overall sentiment is cautiously optimistic, with clear winners in AI and infrastructure, but growing risks in consumer discretionary and real estate segments.

21 high priority 29 medium 50 total filings